These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Non-invasive detection of acute renal allograft rejection by measurement of vascular endothelial growth factor in urine.
    Author: Peng W, Chen J, Jiang Y, Shou Z, Chen Y, Wang H.
    Journal: J Int Med Res; 2007; 35(4):442-9. PubMed ID: 17697520.
    Abstract:
    Urinary vascular endothelial growth factor (VEGF) was determined by enzyme-linked immunosorbent assay in 199 renal allograft recipients and 80 healthy controls. Urinary VEGF level did not change significantly during the first 8 weeks after transplantation in 119 patients with stable renal function and there were no abnormal histological findings (No-AR). In 67 patients with acute rejection, urinary VEGF was significantly higher (28.57 +/- 6.21 pg/micromol creatinine) than in the No-AR patients (3.05 +/- 0.45 pg/micromol creatinine) and healthy controls (2.87 +/- 0.35 pg/micromol creatinine). At a cut-off point of 3.26 pg/micromol creatinine, sensitivity and specificity for diagnosis of acute rejection were 86.6 and 71.4%, respectively. The 13 patients with subclinical rejection excreted urinary VEGF (16.14 +/- 4.09 pg/micromol creatinine) at a significantly higher level than No-AR patients (3.05 +/- 0.45 pg/micromol creatinine). At a cut-off point of 4.69 pg/micromol creatinine, sensitivity and specificity for diagnosis of subclinical rejection were 84.6 and 79.8%, respectively. In conclusion, monitoring VEGF in urine might offer a new non-invasive way to detect acute and subclinical rejection in renal transplant recipients.
    [Abstract] [Full Text] [Related] [New Search]